On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- HIV life cycle
- The HIV-1 genome
- Synthesis of HIV-1 envelope glycoproteins
- HIV life cycle: targets for antiretroviral therapy
- Mechanism of HIV-1 entry
- HIV-1 binding inhibitors
- Polyanions as inhibitors of HIV attachment
- Small-molecule inhibitors of CD4-gp120 interaction
- HIV-1 coreceptor inhibitors
- Coreceptor usage of HIV-1 variants
- Viral composition of pure/mixed populations
- CXCR4 antagonists with potent anti-HIV activity
- Drugs blocking gp120 - CCR5 interaction
- Maraviroc
- Activity of maraviroc
- MOTIVATE 1 and 2 clinical trials
- Coreceptor tropism by treatment status
- Resistance in the absence of coreceptors
- Second generation HIV entry inhibitors
- HIV-1 fusion inhibitors
- Mechanism of gp41 dependant fusion
- Fusion inhibitors: enfuvirtide (T20)
- TORO trials
- Predictors of virological response
- Limitations for the use of enfuvirtide
- Resistance to enfuvirtide
- Second generation fusion inhibitors
- The discovery of virus-inhibitory peptide (virip)
- Pilot phase I/II clinical trial of vir576
- Future perspectives for HIV entry
- Future perspectives for HIV entry: gene therapy
- New strategies to prevent HIV infection
- Hematopoietic cells targeted to CCR5
- Conclusions
Topics Covered
- HIV life cycle
- The HIV-1 genome
- Synthesis of HIV-1 envelope glycoproteins
- Targets for antiretroviral therapy
- Mechanism of HIV-1 entry
- HIV entry inhibition
- HIV-1 binding inhibitors
- HIV-1 coreceptor inhibitors
- Viral composition of pure/mixed populations
- CXCR4 antagonists
- Drugs blocking gp120-CCR5 interaction
- Maraviroc
- MOTIVATE 1 and 2 clinical trials
- Coreceptor tropism by treatment status
- Resistance in the absence of coreceptors
- HIV-1 fusion inhibitors
- TORO trials
- Predictors of virological response
- The virus-inhibitory peptide (virip)
- New strategies to prevent HIV infection
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Esté, J. (2011, August 30). HIV entry inhibitors [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/RYTI5236.Export Citation (RIS)
Publication History
- Published on August 30, 2011
Financial Disclosures
- Prof. José Esté has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.